SCHEMBL4892563

SCHEMBL4892563

Cc1ccccc1-c1ccc2nc(Nc3ccc(N4CCOCC4)cc3)ncc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND3 P30281 2/20 0.56
CCNK O75909 1/20 0.56
CCNA2 P20248 1/20 0.56
CDK2 P24941 1/20 0.56
CDK9 P50750 1/20 0.56
CDK6 Q00534 1/20 0.56
MYLK4 Q86YV6 2/20 0.56
STK17A Q9UEE5 2/20 0.56
JAK2 O60674 4/20 0.54
JAK3 P52333 2/20 0.54
MAP4K1 Q92918 1/20 0.52
MAPK1 P28482 3/20 0.51
MAPT P10636 2/20 0.51
TP53 P04637 1/20 0.51
ALDH1A1 P00352 2/20 0.51
IGF1R P08069 2/20 0.51
LMNA P02545 1/20 0.51
GAA P10253 1/20 0.51
PTK2B Q14289 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3041756 0.81 MYLK4 (0.62) MYLK4STK17AJAK2MAP4K1MAPK10
SCHEMBL20516536 0.80 RIPK2 (0.67) CCND3CCNKCCNA2CDK2CDK9
SCHEMBL5501445 0.79 MAP4K1 (0.64) CCND3CCNKCCNA2CDK2CDK9
SCHEMBL1866937 0.79 MAPT (0.60) CCND3MYLK4STK17AMAPK1MAPT
SCHEMBL4891700 0.78 CLK4 (0.67) MAPK1MAPTTP53ALDH1A1LMNA
SCHEMBL3504564 0.78 STK17A (0.58) CCND3MYLK4STK17AJAK2MAP4K1
SCHEMBL226380 0.78 STK17A (0.58) CCND3CCNA2CDK2MYLK4STK17A
SCHEMBL5502267 0.78 RIPK1 (0.70) JAK3MAPK1ALDH1A1LMNATSHR
SCHEMBL5494435 0.78 MAP4K1 (0.57) STK17AMAP4K1CDK4CCND1SYK
SCHEMBL5494563 0.77 RIPK1 (0.63) JAK3MAPK1ALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 CCND3 70/4885CCNK 112/4885CCNA2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.